Table 2. Tissue acquisition methods and quality measures.
| Characteristics | No. (%) | |
|---|---|---|
| Specimen type | ||
| Biopsy | 82 (60) | |
| Resection | 55 (40) | |
| Biopsy site | ||
| Breast | 50 (36) | |
| Liver | 26 (19) | |
| Lymph node | 18 (13) | |
| Lung | 14 (10) | |
| Skin/Soft tissue | 10 (7) | |
| Bone | 8 (6) | |
| Others* | 11 (9) | |
| Prior CT before tissue acquisition | 84 (61) | |
| Anthracycline | 66 (48) | |
| Taxane | 72 (53) | |
| No. of prior lines of CT, median (range) | 2 (1–7) | |
| Prior ET before tissue acquisition | 63 (46) | |
| No. of prior lines of ET, median (range) | 1 (1–4) | |
| Tumor fraction, median (range) | 70 (20–90) | |
| Mean depth, median (range) | 755 (249–2,565) | |
| 100× coverage (%), median (range) | 96.52 (75.46–99.72) | |
| 100× coverage ≥ 95% (pass) | 93 (68) | |
| 95 > 100× coverage ≥ 80% (caution) | 43 (31) | |
| 100× coverage < 80% (fail) | 1 (1) | |
CT, chemotherapy; ET, endocrine therapy.
*Ovary, chest wall (n = 3, respectively), pleura, brain (n = 2, respectively), mediastinum (n = 1).